Metabolic Effects of Tirzepatide and Semaglutide: Energy Expenditure and Adaptations During and After Treatment​

Background & aim:

Obesity pharmacotherapy has significantly improved weight management, with semaglutide (GLP-1 receptor agonist) and tirzepatide (dual GLP-1 and GIP receptor agonist) demonstrating substantial efficacy in reducing body weight. These drugs primarily act by suppressing appetite and improving glucose metabolism. However, their acute and long-term effects on energy expenditure and metabolic adaptations following treatment withdrawal’ remain poorly understood. The present study aimed to characterize the effect of semaglutide and tirzepatide on chronic energy expenditure in diet-induced obese mice at thermoneutrality.